About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) group arises from the merger of two VHIR groups, the Clinical Biochemistry group and the Drug Delivery and Targeting group, which they develop preclinical and clinical research in the diagnosis and therapy of different diseases.
With a direct link to the Clinical Biochemistry service of the Vall d'Hebron Hospital, our scope of action ranges from the analysis of massive data coming from the service, the development of diagnostic and prognostic biomarkers, evaluation of existing therapies and the development of new therapeutic strategies based on nanotechnology.
In terms of specific pathologies or indications, the group has an extensive track record in basic and applied research in cancer (new biomarkers, therapeutic targets and new treatments), metabolopathies (biomarkers and improvements in enzyme replacement therapy), kidney disease and liver disease.
IP: Fernanda Raquel Da Silva Andrade
IP: Joaquin Seras Franzoso
IP: Maria del Pilar Reimundo Diaz-Fierros
IP: Ibane Abasolo Olaortua
IP: Begoña Benito Villabriga Collaborators: Carmen Escudero Iriarte, Laia Ventura i Expósito, Susana Otero Romero, Ibane Abasolo Olaortua, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, María Rosario Pérez- Torres Lobato, Sunny Malhotra Sareen, Belen Perez Dueñas, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Joaquin Seras Franzoso, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, Julia German Cortes, Maria Jose Pérez García, Miguel Segura Ginard, Diego Baranda Martínez-Abasca, Cristina Auger Acosta, Neus Bellera Gotarda, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno García del Blanco, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, Xavier Montalban Gairín, Simon Schwartz Navarro, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Angels Alcina Mila, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Ana Zabalza de Torres, TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas, Marc Miquel Moltó Abad, Javier Inserte Igual, Luciana Midaglia Fernandez, Elizabeth Pando Rau, Gabriela Guillén Burrieza, Ana Laura Cazurro Gutierrez, David Gómez Andrés, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lydia Dux-Santoy Hurtado, Lucas Moreno Martín-Retortillo, TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas, Josep Roma Castanyer, Laura Dos Subirá, Nicolás Miguel Fissolo, Maria Nazarena Pizzi, Tian Tian, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Andrea Guala Funding agency: Instituto de Salud Carlos III Funding: 2494527.53 Reference: FORT23/00034 Duration: 01/01/2024 - 31/12/2027
IP: José Antonio Barrabés Riu Collaborators: Ignacio Ferreira González, David Aluja Gonzalez, Sara Delgado Tomás, Laura Castellote Bellés, Javier Inserte Igual Funding agency: -Sociedad Española de Cardiologia Funding: 15000 Reference: SEC/FEC-INV-BAS 23/11 Duration: 26/10/2023 - 31/12/2027
IP: Joaquin Seras Franzoso Collaborators: Maria Fidel Lledò, Miriam Izquierdo Sans Funding agency: Instituto de Salud Carlos III Funding: 119567 Reference: FI23/00223 Duration: 15/01/2024 - 14/01/2028
IP: David Martinez Selva Collaborators: Maria Teresa Salcedo Allende, Lorena Ramos Pérez, Pablo Gabriel Medina, Pilar Costa Forner Funding agency: Instituto de Salud Carlos III Funding: 190000 Reference: PI23/00544 Duration: 01/01/2024 - 31/12/2026
PMID: 37376135 Journal: Pharmaceutics Year: 2023 Reference: Pharmaceutics. 2023 Jun 8;15(6):1686. doi: 10.3390/pharmaceutics15061686. Impact factor: Publication type: Review in international publication Authors: Abasolo, Ibane; Andrade, Fernanda; Baranda-Martinez-Abascal, Diego; Carcavilla, Pilar; Diaz-Riascos, Zamira Vanessa; German-Cortes, Julia; Molto-Abad, Marc; Montero, Sara; Rafael, Diana; Seras-Franzoso, Joaquin et al. DOI: 10.3390/pharmaceutics15061686
PMID: 37443087 Journal: Orphanet Journal of Rare Diseases Year: 2023 Reference: Orphanet J Rare Dis. 2023 Jul 13;18(1):188. doi: 10.1186/s13023-023-02793-4. Impact factor: Publication type: Letter or abstract Authors: Argudo, Ana; Arranz, Jose Antonio; Artuch, Rafael; Carnicer, Clara; de Aledo-Castillo, Jose Manuel Gonzalez; de Los Santos, Mariela Mercedes; Fernandez, Rosa; Garcia-Cazorla, Angeles; Garcia-Villoria, Judit; Garcia-Volpe, Camila et al. DOI: 10.1186/s13023-023-02793-4
PMID: 37555464 Journal: BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY Year: 2023 Reference: BJOG. 2023 Aug 9. doi: 10.1111/1471-0528.17631. Impact factor: Publication type: Paper in international publication Authors: Alsius, Merce; Bonacina, Erika; Caamina, Sara; Carreras, Elena; Castillo-Ribelles, Laura; de Mingo, Laura; Diaz, Sonia; Garcia, Esperanza; Garcia-Manau, Pablo; Lopez, Monica et al. DOI: 10.1111/1471-0528.17631
PMID: 37570527 Journal: Nanomaterials Year: 2023 Reference: Nanomaterials (Basel). 2023 Jul 29;13(15):2208. doi: 10.3390/nano13152208. Impact factor: Publication type: Paper in international publication Authors: Abasolo, Ibane; Bastus, Neus G; Boullosa, Ana Maria; Camara, Juan Antonio; Casals, Eudald; Garcia, Ana; Gusta, Muriel F; Mondragon, Laura; Puntes, Victor; Schwartz, Simo Jr et al. DOI: 10.3390/nano13152208
The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.
The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.
Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.
